Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva shares surge on corporate shake-up - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
FDA approves first rival generic EpiPen, sending Teva shares up 6% - MarketWatch
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva Pharmaceutical CEO Talks Opioids, Lawsuits, and the Long Road Ahead | Barron's
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Generic-drug stocks slammed by report of expanded price-fixing probe - MarketWatch
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva's Stock Slides After U.S. Sues Over Copay Kickback Claims | Barron's
Bulk of earnings pressure in the first half of 2023, says Citi's Scott Chronert
Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis - MarketWatch
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Teva Stock Has Crumbled, and Chairman Sol Barer Is Buying Up Shares | Barron's
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
